Tempus AI (1TEM) Stock Overview

Operates as a healthcare technology company. More details

1TEM fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 49.8% below our estimate of its fair value

Revenue is forecast to grow 20.68% per year

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Significant insider selling over the past 3 months

1TEM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Tempus AI, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tempus AI
Historical stock prices
Current Share Price	US$63.74
52 Week High	US$0
52 Week Low	US$0
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	8.66%

Recent updates

Shareholder Returns

	1TEM	IT Life Sciences	IT Market
7D	n/a	4.7%	1.1%
1Y	n/a	-0.5%	28.4%

Return vs Industry: Insufficient data to determine how 1TEM performed against the Italian Life Sciences industry.

Return vs Market: Insufficient data to determine how 1TEM performed against the Italian Market.

Price Volatility

Is 1TEM's price volatile compared to industry and market?
1TEM volatility
1TEM Average Weekly Movement	n/a
Life Sciences Industry Average Movement	5.8%
Market Average Movement	4.3%
10% most volatile stocks in IT Market	7.4%
10% least volatile stocks in IT Market	2.5%

Stable Share Price: 1TEM's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1TEM's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	2,400	Eric Lefkofsky	www.tempus.com

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies.

Tempus AI, Inc. Fundamentals Summary

How do Tempus AI's earnings and revenue compare to its market cap?
1TEM fundamental statistics
Market cap	€11.84b
Earnings (TTM)	-€175.78m
Revenue (TTM)	€952.95m

12.4x

P/S Ratio

-67.4x

P/E Ratio

Is 1TEM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1TEM income statement (TTM)
Revenue	US$1.11b
Cost of Revenue	US$423.01m
Gross Profit	US$682.25m
Other Expenses	US$886.12m
Earnings	-US$203.88m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-1.15
Gross Margin	61.73%
Net Profit Margin	-18.45%
Debt/Equity Ratio	245.3%

How did 1TEM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/27 02:03
End of Day Share Price	2025/11/27 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tempus AI, Inc. is covered by 18 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Ryskin	BofA Global Research
Mark Massaro	BTIG
Kyle Mikson	Canaccord Genuity

Tempus AI, Inc.BIT:1TEM Stock Report